Pliant Therapeutics, Inc.(PLRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PLRX Pliant Therapeutics, Inc.

盘前交易 09-22 06:28:43 EDT

1.11

+0.00

0.00%

最高1.13	最低1.11	成交量14.93万
今开1.12	昨收1.11	日振幅1.80%
总市值6,873万	流通市值6,109万	总股本6,191万
成交额16.71万	换手率0.27%	流通股本5,503万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PLRX","market":"US","secType":"STK","nameCN":"Pliant Therapeutics, Inc.","latestPrice":1.11,"timestamp":1790020800000,"preClose":1.11,"halted":0,"volume":149288,"delay":0,"changeRate":0,"floatShares":55033600,"shares":61914664,"eps":-1.5,"marketStatus":"盘前交易","change":0,"latestTime":"09-22 06:28:43 EDT","open":1.12,"high":1.13,"low":1.11,"amount":167127.826427,"amplitude":0.018018,"askPrice":1.22,"askSize":100,"bidPrice":1.01,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.5,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790083800000},"marketStatusCode":1,"adr":0,"listingDate":1591156800000,"exchange":"NASDAQ","adjPreClose":1.11,"postHourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.11,"latestTime":"19:30 EDT","volume":15,"amount":16.65,"timestamp":1790033403296,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.3058240294176849,"impliedVol":2.2077,"impliedVolPercentile":0.84},"requestUrl":"/m/hq/s/PLRX","defaultTab":"news","newsList":[{"id":"1193114838","title":"Pliant Therapeutics获FDA快速通道资格认定：PLN-101095联合帕博利珠单抗治疗ICI难治性实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1193114838","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193114838?lang=zh_cn&edition=full","pubTime":"2026-08-18 20:31","pubTimestamp":1787056273,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics宣布，其候选药物PLN-101095与帕博利珠单抗联用，已获得美国食品药品监督管理局授予的快速通道资格认定，旨在用于治疗对免疫检查点抑制剂耐药的实体瘤患者。获得快速通道资格后，Pliant Therapeutics将有更多机会与FDA进行密切沟通，并可能加快该疗法的开发与审评进程，从而尽早将这一潜在新疗法带给患者。公司表示，PLN-101095作为一种新型在研药物，其与帕博利珠单抗的联合方案有望为ICI难治性实体瘤患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168441388","title":"Pliant Therapeutics 第二季度净收入为负2237.1万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168441388","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168441388?lang=zh_cn&edition=full","pubTime":"2026-08-12 04:24","pubTimestamp":1786479863,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics, Inc. 第二季度业绩揭晓：净收入录得负2237.1万美元。与此同时，该公司的运营支出也颇为可观，达到了负2386.2万美元。这一系列数字，勾勒出其在研发投入与市场拓展上的持续发力，也反映出生物科技公司普遍面临的盈利压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135305448","title":"Pliant Therapeutics 任命 Flavia Borellini 博士与 Robert Iannone 博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1135305448","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135305448?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:32","pubTimestamp":1783945951,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics 宣布，Flavia Borellini 博士以及 Robert Iannone 医学博士、理学硕士已获任命加入公司董事会。此项人事变动旨在为公司治理带来新的专业视角与丰富经验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106450316","title":"Pliant Therapeutics宣布首位患者接受Fortify试验用药，评估Pln-101095治疗ICI难治性实体瘤的IB期适应症扩展研究启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1106450316","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106450316?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:31","pubTimestamp":1777552307,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics宣布，其针对ICI难治性实体瘤患者的IB期适应症扩展试验\"Fortify\"已完成首位患者给药。该试验旨在评估候选药物Pln-101095的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126176780","title":"Pliant Therapeutics公司PLN-101095总体耐受性良好 最常见不良事件为皮疹 仅观察到1例3级不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1126176780","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126176780?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:34","pubTimestamp":1776533654,"startTime":"0","endTime":"0","summary":"生物制药公司Pliant Therapeutics宣布其候选药物PLN-101095在临床试验中展现出良好的安全性特征。该药物总体耐受性良好，其中皮疹是最常见的不良反应类型。研究过程中仅报告1例3级严重程度的不良事件，未出现更高等级的安全性信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518230664","title":"Pliant Therapeutics, Inc.2024财年实现净利润-2.10亿美元，同比减少30.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518230664","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518230664?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449685,"startTime":"0","endTime":"0","summary":"3月9日，Pliant Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.10亿美元，同比减少30.43%；其中营业收入为0.00美元，每股基本收益为-3.47美元。从资产负债表来看，Pliant Therapeutics, Inc.总负债92.87百万美元，其中短期债务542000.00美元，资产负债比为0.05，流动比率为0.11。机构评级：截至2025年3月9日，当前有7家机构对Pliant Therapeutics, Inc.目标价做出预测，其中目标均价为4.79美元，其中最低目标价为1.50美元，最高目标价为17.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000305abef98db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000305abef98db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517604941","title":"花旗：维持Pliant Therapeutics(PLRX.US)评级，由中性调整至中性评级, 目标价由4.00美元调整至1.50美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517604941","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517604941?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:23","pubTimestamp":1741108999,"startTime":"0","endTime":"0","summary":"花旗：维持Pliant Therapeutics(PLRX.US)评级，由中性调整至中性评级, 目标价由4.00美元调整至1.50美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05012348524105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PLRX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516566777","title":"Pliant Therapeutics(PLRX.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为8.333万美元；每股收益为-0.82美元，前值为-0.69美元，预期值为-0.98美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516566777","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516566777?lang=zh_cn&edition=full","pubTime":"2025-03-04 07:12","pubTimestamp":1741043551,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics(PLRX.US)：2024年Q4财报实现营收0美元，前值为0美元，预期值为8.333万美元；每股收益为-0.82美元，前值为-0.69美元，预期值为-0.98美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04071248499312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PLRX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516664947","title":"Leerink Partners：下调Pliant Therapeutics(PLRX.US)评级，由优于大市调整至大市一致评级, 目标价由33.00美元调整至2.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516664947","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516664947?lang=zh_cn&edition=full","pubTime":"2025-03-04 06:04","pubTimestamp":1741039467,"startTime":"0","endTime":"0","summary":"Leerink Partners：下调Pliant Therapeutics(PLRX.US)评级，由优于大市调整至大市一致评级, 目标价由33.00美元调整至2.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04060448499226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PLRX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158493154","title":"Pliant Therapeutics 2024年第四季度GAAP每股收益$(0.82), 超过预期$(0.98)","url":"https://stock-news.laohu8.com/highlight/detail?id=1158493154","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158493154?lang=zh_cn&edition=full","pubTime":"2025-03-04 05:12","pubTimestamp":1741036357,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics报告季度亏损每股$，比分析师一致预期的$高16.33%。这比去年同期每股亏损$减少了18.84%。以上内容来自Benzinga Earnings专栏，原文如下：Pliant $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 16.33 percent. This is a 18.84 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","PLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514065389","title":"Pliant Therapeutics, Inc.盘中异动 股价大涨5.13%报3.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514065389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514065389?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:19","pubTimestamp":1740669557,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时19分，Pliant Therapeutics, Inc.股票出现波动，股价急速上涨5.13%。Pliant Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.87%。其相关个股中，Alpha Tau Medical Ltd C/Wts 、Editas Medicine, Inc.、Quoin Pharmaceuticals Ltd涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为790.25%、162.79%、104.30%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Quoin Pharmaceuticals Ltd，振幅分别为78.88%、43.51%、34.80%。Pliant Therapeutics, Inc.公司简介：Pliant Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现和开发治疗纤维化和相关疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227231917a25686aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227231917a25686aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRX","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510886197","title":"加拿大投资银行集团：下调Pliant Therapeutics(PLRX.US)评级，由买入调整至持有评级, 目标价4.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510886197","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510886197?lang=zh_cn&edition=full","pubTime":"2025-02-10 23:41","pubTimestamp":1739202086,"startTime":"0","endTime":"0","summary":"加拿大投资银行集团：下调Pliant Therapeutics(PLRX.US)评级，由买入调整至持有评级, 目标价4.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/10234148064202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PLRX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510865876","title":"Pliant Therapeutics, Inc.盘中异动 股价大跌62.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510865876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510865876?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:37","pubTimestamp":1739198256,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时37分，Pliant Therapeutics, Inc.股票出现波动，股价急速下跌62.32%。Pliant Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，Ocean Biomedical, Inc.、Nls Pharmaceutics Ltd.、Solid Biosciences Inc.涨幅较大，Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为987.63%、666.52%、268.46%，振幅较大的相关个股有Soligenix, Inc.、Ocean Biomedical, Inc.、Invivyd, Inc.，振幅分别为103.16%、34.46%、29.90%。Pliant Therapeutics, Inc.公司简介：Pliant Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现和开发治疗纤维化和相关疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223736961e016d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223736961e016d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRX","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510985597","title":"Needham：维持Pliant Therapeutics(PLRX.US)评级，由买入调整至买入评级, 目标价由38.00美元调整至10.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510985597","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510985597?lang=zh_cn&edition=full","pubTime":"2025-02-10 19:54","pubTimestamp":1739188461,"startTime":"0","endTime":"0","summary":"Needham：维持Pliant Therapeutics(PLRX.US)评级，由买入调整至买入评级, 目标价由38.00美元调整至10.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/10195448056203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","PLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509202744","title":"Pliant Therapeutics, Inc.盘中异动 股价大跌5.19%报11.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509202744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509202744?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:32","pubTimestamp":1738938724,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日22时32分，Pliant Therapeutics, Inc.股票出现异动，股价快速跳水5.19%。截至发稿，该股报11.33美元/股，成交量1.4966万股，换手率0.02%，振幅4.10%。Pliant Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Pliant Therapeutics, Inc.公司简介：Pliant Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现和开发治疗纤维化和相关疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223204a23d2368&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223204a23d2368&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRX","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503642104","title":"Pliant Therapeutics, Inc.盘中异动 急速上涨5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503642104","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503642104?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:31","pubTimestamp":1736951473,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时31分，Pliant Therapeutics, Inc.股票出现异动，股价快速拉升5.25%。Pliant Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Os Therapies Incorporated、Generation Bio Co.、Exicure, Inc.涨幅较大，Windtree Therapeutics, Inc.、Os Therapies Incorporated、Phio Pharmaceuticals Corp.较为活跃，换手率分别为184.25%、56.33%、51.74%，振幅较大的相关个股有Os Therapies Incorporated、Klotho Neurosciences, Inc.、Vincerx Pharma, Inc.，振幅分别为18.99%、12.00%、10.72%。Pliant Therapeutics, Inc.公司简介：Pliant Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现和开发治疗纤维化和相关疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223114ababf1fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223114ababf1fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRX","BK4139","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2488677810","title":"Pliant Therapeutics, Inc.盘中异动 急速拉升5.07%报14.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488677810","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2488677810?lang=zh_cn&edition=full","pubTime":"2024-12-02 22:49","pubTimestamp":1733150986,"startTime":"0","endTime":"0","summary":"北京时间2024年12月02日22时49分，Pliant Therapeutics, Inc.股票出现异动，股价快速拉升5.07%。截至发稿，该股报14.50美元/股，成交量16.132万股，换手率0.27%，振幅4.20%。Pliant Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.05%。Pliant Therapeutics, Inc.公司简介：Pliant Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现和开发治疗纤维化和相关疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202224946abf00aba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202224946abf00aba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRX","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2482267361","title":"Pliant Therapeutics, Inc.2024财年第三财季实现净利润-57.76百万美元，同比减少39.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482267361","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2482267361?lang=zh_cn&edition=full","pubTime":"2024-11-11 00:00","pubTimestamp":1731254427,"startTime":"0","endTime":"0","summary":"11月11日，Pliant Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-57.76百万美元，同比减少39.21%；其中营业收入为0.00美元，每股基本收益为-0.95美元。机构评级：截至2024年11月11日，当前有11家机构对Pliant Therapeutics, Inc.目标价做出预测，其中目标均价为40.18美元，其中最低目标价为32.00美元，最高目标价为47.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000036abb36226&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000036abb36226&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2481123985","title":"Pliant Therapeutics, Inc.盘中异动 股价大涨5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481123985","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481123985?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:30","pubTimestamp":1730903431,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时30分，Pliant Therapeutics, Inc.股票出现波动，股价快速上涨5.44%。Pliant Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Macrogenics, Inc.、Theratechnologies Inc.、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Sonnet Biotherapeutics Holdings, Inc.、Elevai Labs, Inc.、Zyversa Therapeutics, Inc.较为活跃，换手率分别为1007.85%、97.66%、45.48%，振幅较大的相关个股有诺瓦瓦克斯医药、Ovid Therapeutics Inc.、Elevai Labs, Inc.，振幅分别为96.72%、8.00%、7.48%。Pliant Therapeutics, Inc.公司简介：Pliant Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现和开发治疗纤维化和相关疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223031971a4b5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223031971a4b5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PLRX","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2477893747","title":"Pliant Therapeutics, Inc.盘中异动 急速跳水5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477893747","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2477893747?lang=zh_cn&edition=full","pubTime":"2024-10-22 00:24","pubTimestamp":1729527897,"startTime":"0","endTime":"0","summary":"北京时间2024年10月22日00时24分，Pliant Therapeutics, Inc.股票出现波动，股价急速跳水5.00%。Pliant Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.56%。其相关个股中，Genprex, Inc.、Biovie Inc.、Gri Bio, Inc.涨幅较大，Genprex, Inc.、Gri Bio, Inc.、Biovie Inc.较为活跃，换手率分别为7383.13%、3333.00%、1460.16%，振幅较大的相关个股有Genprex, Inc.、Biovie Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为369.73%、157.02%、148.15%。Pliant Therapeutics, Inc.公司简介：Pliant Therapeutics Inc 是一家临床阶段的生物制药公司，专注于发现和开发治疗纤维化和相关疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102200245798e3d950&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102200245798e3d950&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PLRX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://pliantrx.com","stockEarnings":[{"period":"1week","weight":-0.0348},{"period":"1month","weight":-0.039},{"period":"3month","weight":-0.0431},{"period":"6month","weight":-0.1527},{"period":"1year","weight":-0.2238},{"period":"ytd","weight":-0.0902}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":0.0102},{"period":"3month","weight":0.0544},{"period":"6month","weight":0.1776},{"period":"1year","weight":0.1654},{"period":"ytd","weight":0.1343}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pliant Therapeutics, Inc. 于2015年6月根据特拉华州法律注册成立。该公司是一家临床阶段生物制药公司，致力于发现和开发用于治疗纤维化的新疗法。 他们最初的重点是通过抑制整合素介导的TGF-β活化来治疗纤维化。 该公司利用他们对纤维化生物学的深刻理解，以及他们在药物化学和转化医学方面的专业知识，开发了一套专有工具，旨在快速有效地发现和降低候选产品的风险。 他们的全资主要候选药物PLN-74809是整合素的口服小分子双重选择性抑制剂，该公司正在开发该药物用于治疗特发性肺纤维化或IPF，原发性硬化性胆管炎或PSC。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.093727},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.116915},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.149079},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.051822},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.078033},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.020093},{"month":7,"riseRate":0.428571,"avgChangeRate":0.152333},{"month":8,"riseRate":0.571429,"avgChangeRate":0.02124},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.044027},{"month":10,"riseRate":0.5,"avgChangeRate":0.054175},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.035324},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.025793}],"exchange":"NASDAQ","name":"Pliant Therapeutics, Inc.","nameEN":"Pliant Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pliant Therapeutics, Inc.(PLRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pliant Therapeutics, Inc.(PLRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pliant Therapeutics, Inc.,PLRX,Pliant Therapeutics, Inc.股票,Pliant Therapeutics, Inc.股票老虎,Pliant Therapeutics, Inc.股票老虎国际,Pliant Therapeutics, Inc.行情,Pliant Therapeutics, Inc.股票行情,Pliant Therapeutics, Inc.股价,Pliant Therapeutics, Inc.股市,Pliant Therapeutics, Inc.股票价格,Pliant Therapeutics, Inc.股票交易,Pliant Therapeutics, Inc.股票购买,Pliant Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pliant Therapeutics, Inc.(PLRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pliant Therapeutics, Inc.(PLRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}